Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Cash from Operations (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Cash from Operations data on record, last reported at 3732000.0 in Q3 2025.

  • For Q3 2025, Cash from Operations fell 190.91% year-over-year to 3732000.0; the TTM value through Sep 2025 reached 10032000.0, down 221.19%, while the annual FY2024 figure was 8674000.0, 758.12% up from the prior year.
  • Cash from Operations reached 3732000.0 in Q3 2025 per PLX's latest filing, up from 5233000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 6516000.0 in Q2 2021 and bottomed at 9834000.0 in Q1 2021.
  • Average Cash from Operations over 5 years is 2208000.0, with a median of 3610000.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: crashed 389.57% in 2022, then skyrocketed 239.69% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 5087000.0 in 2021, then soared by 48.67% to 2611000.0 in 2022, then soared by 237.69% to 3595000.0 in 2023, then grew by 11.02% to 3991000.0 in 2024, then crashed by 193.51% to 3732000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 3732000.0 in Q3 2025, 5233000.0 in Q2 2025, and 5058000.0 in Q1 2025.